Trials / Completed
CompletedNCT01296932
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 836826 | Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion. |
Timeline
- Start date
- 2011-02-11
- Primary completion
- 2017-05-30
- Completion
- 2017-07-10
- First posted
- 2011-02-16
- Last updated
- 2020-08-20
- Results posted
- 2020-08-20
Locations
10 sites across 3 countries: Belgium, France, Germany
Source: ClinicalTrials.gov record NCT01296932. Inclusion in this directory is not an endorsement.